Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda. The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among other factors. Shares of Merck fell more than 2% in premarket trading Thursday. Sales of Keytruda topped $8 billion…

Read More